Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) has signed a conditional agreement to issue 25.00 million new H shares to Baheal Wellness Industry International Trading Ltd., a wholly owned unit of Qingdao Baheal Pharmaceutical Co., Ltd.
The shares will be placed at HK$4.00 each, matching the five-day average closing price and carrying a discount of no more than 20%. Gross and net proceeds are both estimated at HK$100.00 million.
Key terms and effects:
• Dilution: The new shares equate to 6.86% of Biostar’s existing 364.59 million shares and will expand the share base to 389.59 million, cutting existing shareholders’ stake proportionately. • Subscriber stake: Baheal currently owns 4.17 million shares (1.14%). Post-placement, its holding will rise to 29.17 million shares (7.49%). • Mandate: The issue falls under the general mandate allowing up to 72.92 million new shares (20% of share capital) approved at the upcoming AGM on 26 June 2026. • Conditions: Completion requires shareholder approval, Hong Kong Stock Exchange listing consent, CSRC filing, due-diligence clearance, and other regulatory nods by the one-month long-stop date. Closing is scheduled for the fifth business day after all conditions are met. • Ranking: The subscription shares will rank pari passu with existing shares and be free of encumbrances.
Planned use of proceeds (to be deployed by end-2027):
1. Development of antibody-drug conjugate (ADC) products and platforms – 50% 2. Commercialisation cooperation – 20% 3. New project introduction and achievement transformation – 15% 4. Group daily operations – 15%
Strategic rationale: The transaction deepens the oncology partnership that began in 2024 between Biostar and Baheal, combining Biostar’s R&D pipeline with Baheal’s commercial platforms. No equity fundraising was conducted by Biostar in the previous 12 months.
Shareholders and investors are advised that completion remains subject to the stated conditions.
Comments